R ± BEACOP for Treating Newly Diagnosed, Moderate and High Risk Diffuse Large B Cell Lymphoma Patients.
- Author:
Fei DONG
1
;
Jing WANG
1
;
Ping YAND
1
;
Wei ZHAO
1
;
Hong-Mei JING
1
;
Xiao-Yan KE
2
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; China; Humans; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Retrospective Studies
- From: Journal of Experimental Hematology 2015;23(6):1591-1595
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of R ± BEACOP protocol on newly diagnosed patients with moderate and high risk diffuse large B-cell lymphoma (DLBCL).
METHODSThe clinical data of 19 newly diagnosed patients with moderate and high risk DLBCL received at least 2 cycles of R ± BEACOP protocol during 2011 to 2014 were collected, their therapeutic efficacy and side effects were evaluated by retrospective analysis.
RESULTSThe overall response rate of 19 assessable patients was 94.7%, including 5 patients (26.3%) in complete remission (CR) and 13 patients (68.4%) in partial remission (PR). The major toxicity was hematologic toxicity and the incidence of grade III-IV hematologic toxicity was 73.7%. Other toxicities were mild and no treatment-related death occurred.
CONCLUSIONR ± BEACOP protocol is a effective and safe protocol for the patients with DLBCL which is worth further multicenter prospectively studying in china.
